Nikhil R Oak1, Jonathan P Gumucio2, Michael D Flood1, Anjali L Saripalli1, Max E Davis1, Julie A Harning1, Evan B Lynch2, Stuart M Roche1, Asheesh Bedi1, Christopher L Mendias3. 1. Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. 2. Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, USA. 3. Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, USA cmendias@umich.edu.
Abstract
BACKGROUND: The repair and restoration of function after chronic rotator cuff tears are often complicated by muscle atrophy, fibrosis, and fatty degeneration of the diseased muscle. The inflammatory response has been implicated in the development of fatty degeneration after cuff injuries. Licofelone is a novel anti-inflammatory drug that inhibits 5-lipoxygenase (5-LOX), as well as cyclooxygenase (COX)-1 and COX-2 enzymes, which play important roles in inducing inflammation after injuries. While previous studies have demonstrated that nonsteroidal anti-inflammatory drugs and selective inhibitors of COX-2 (coxibs) may prevent the proper healing of muscles and tendons, studies about bone and cartilage have demonstrated that drugs that inhibit 5-LOX concurrently with COX-1 and COX-2 may enhance tissue regeneration. HYPOTHESIS: After the repair of a chronic rotator cuff tear in rats, licofelone would increase the load to failure of repaired tendons and increase the force production of muscle fibers. STUDY DESIGN: Controlled laboratory study. METHODS: Rats underwent supraspinatus release followed by repair 28 days later. After repair, rats began a treatment regimen of either licofelone or a vehicle for 14 days, at which time animals were euthanized. Supraspinatus muscles and tendons were then subjected to contractile, mechanical, histological, and biochemical analyses. RESULTS: Compared with controls, licofelone-treated rats had a grossly apparent decrease in inflammation and increased fibrocartilage formation at the enthesis, along with a 62% increase in the maximum load to failure and a 51% increase in peak stress to failure. Licofelone resulted in a marked reduction in fibrosis and lipid content in supraspinatus muscles as well as reduced expression of several genes involved in fatty infiltration. Despite the decline in fibrosis and fat accumulation, muscle fiber specific force production was reduced by 23%. CONCLUSION: The postoperative treatment of cuff repair with licofelone may reduce fatty degeneration and enhance the development of a stable bone-tendon interface, although decreases in muscle fiber specific force production were observed, and force production in fact declined. CLINICAL RELEVANCE: This study demonstrates that the inhibition of 5-LOX, COX-1, and COX-2 modulates the healing process of repaired rotator cuff tendons. Although further studies are necessary, the treatment of patients with licofelone after cuff repair may improve the development of a stable enthesis and enhance postoperative outcomes.
BACKGROUND: The repair and restoration of function after chronic rotator cuff tears are often complicated by muscle atrophy, fibrosis, and fatty degeneration of the diseased muscle. The inflammatory response has been implicated in the development of fatty degeneration after cuff injuries. Licofelone is a novel anti-inflammatory drug that inhibits 5-lipoxygenase (5-LOX), as well as cyclooxygenase (COX)-1 and COX-2 enzymes, which play important roles in inducing inflammation after injuries. While previous studies have demonstrated that nonsteroidal anti-inflammatory drugs and selective inhibitors of COX-2 (coxibs) may prevent the proper healing of muscles and tendons, studies about bone and cartilage have demonstrated that drugs that inhibit 5-LOX concurrently with COX-1 and COX-2 may enhance tissue regeneration. HYPOTHESIS: After the repair of a chronic rotator cuff tear in rats, licofelone would increase the load to failure of repaired tendons and increase the force production of muscle fibers. STUDY DESIGN: Controlled laboratory study. METHODS:Rats underwent supraspinatus release followed by repair 28 days later. After repair, rats began a treatment regimen of either licofelone or a vehicle for 14 days, at which time animals were euthanized. Supraspinatus muscles and tendons were then subjected to contractile, mechanical, histological, and biochemical analyses. RESULTS: Compared with controls, licofelone-treated rats had a grossly apparent decrease in inflammation and increased fibrocartilage formation at the enthesis, along with a 62% increase in the maximum load to failure and a 51% increase in peak stress to failure. Licofelone resulted in a marked reduction in fibrosis and lipid content in supraspinatus muscles as well as reduced expression of several genes involved in fatty infiltration. Despite the decline in fibrosis and fat accumulation, muscle fiber specific force production was reduced by 23%. CONCLUSION: The postoperative treatment of cuff repair with licofelone may reduce fatty degeneration and enhance the development of a stable bone-tendon interface, although decreases in muscle fiber specific force production were observed, and force production in fact declined. CLINICAL RELEVANCE: This study demonstrates that the inhibition of 5-LOX, COX-1, and COX-2 modulates the healing process of repaired rotator cuff tendons. Although further studies are necessary, the treatment of patients with licofelone after cuff repair may improve the development of a stable enthesis and enhance postoperative outcomes.
Authors: David Kovacevic; Alice J Fox; Asheesh Bedi; Liang Ying; Xiang-Hua Deng; Russell F Warren; Scott A Rodeo Journal: Am J Sports Med Date: 2011-03-15 Impact factor: 6.202
Authors: Hui B Sun; Yonghui Li; David T Fung; Robert J Majeska; Mitchell B Schaffler; Evan L Flatow Journal: Clin Orthop Relat Res Date: 2008-05-10 Impact factor: 4.176
Authors: Asheesh Bedi; Alice J S Fox; David Kovacevic; Xeng-Hua Deng; Russell F Warren; Scott A Rodeo Journal: Am J Sports Med Date: 2009-10-13 Impact factor: 6.202
Authors: J-P Raynauld; J Martel-Pelletier; P Bias; S Laufer; B Haraoui; D Choquette; A D Beaulieu; F Abram; M Dorais; E Vignon; J-P Pelletier Journal: Ann Rheum Dis Date: 2008-07-23 Impact factor: 19.103
Authors: Christopher L Mendias; Evan B Lynch; Jonathan P Gumucio; Michael D Flood; Danielle S Rittman; Douglas W Van Pelt; Stuart M Roche; Carol S Davis Journal: J Physiol Date: 2015-02-25 Impact factor: 5.182
Authors: Dylan C Sarver; Yalda Ashraf Kharaz; Kristoffer B Sugg; Jonathan P Gumucio; Eithne Comerford; Christopher L Mendias Journal: J Orthop Res Date: 2017-02-09 Impact factor: 3.494
Authors: Benjamin B Rothrauff; Thierry Pauyo; Richard E Debski; Mark W Rodosky; Rocky S Tuan; Volker Musahl Journal: Tissue Eng Part B Rev Date: 2017-02-09 Impact factor: 6.389
Authors: Christopher L Mendias; Andrew J Schwartz; Jeremy A Grekin; Jonathan P Gumucio; Kristoffer B Sugg Journal: J Appl Physiol (1985) Date: 2016-12-15
Authors: Xuhui Liu; Anne Y Ning; Nai Chen Chang; Hubert Kim; Robert Nissenson; Liping Wang; Brian T Feeley Journal: Muscles Ligaments Tendons J Date: 2016-05-19
Authors: Jonathan P Gumucio; Michael D Flood; Stuart M Roche; Kristoffer B Sugg; Adeyiza O Momoh; Paul E Kosnik; Asheesh Bedi; Christopher L Mendias Journal: Int Orthop Date: 2015-07-30 Impact factor: 3.075